Literature DB >> 21440148

The Aristotle Comprehensive Complexity score predicts mortality and morbidity after congenital heart surgery.

Mirela Bojan1, Sébastien Gerelli, Simone Gioanni, Philippe Pouard, Pascal Vouhé.   

Abstract

BACKGROUND: The Aristotle Comprehensive Complexity (ACC) score has been proposed for complexity adjustment in the analysis of outcome after congenital heart surgery. The score is the sum of the Aristotle Basic Complexity score, largely used but poorly related to mortality and morbidity, and of the Comprehensive Complexity items accounting for comorbidities and procedure-specific and anatomic variability. This study aims to demonstrate the ability of the ACC score to predict 30-day mortality and morbidity assessed by the length of the intensive care unit (ICU) stay.
METHODS: We retrospectively enrolled patients undergoing congenital heart surgery in our institution. We modeled the ACC score as a continuous variable, mortality as a binary variable, and length of ICU stay as a censored variable. For each mortality and morbidity model we performed internal validation by bootstrapping and assessed overall performance by R(2), calibration by the calibration slope, and discrimination by the c index.
RESULTS: Among all 1,454 patients enrolled, 30-day mortality rate was 3.4% and median length of ICU stay was 3 days. The ACC score strongly related to mortality, but related to length of ICU stay only during the first postoperative week. For the mortality model, R(2) = 0.24, calibration slope = 0.98, c index = 0.86, and 95% confidence interval was 0.82 to 0.91. For the morbidity model, R(2) = 0.094, calibration slope = 0.94, c index = 0.64, and 95% confidence interval was 0.62 to 0.66.
CONCLUSIONS: The ACC score predicts 30-day mortality and length of ICU stay during the first postoperative week. The score is an adequate tool for complexity adjustment in the analysis of outcome after congenital heart surgery.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440148     DOI: 10.1016/j.athoracsur.2010.10.071

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Surgical management of congenital heart disease: contribution of the Aristotle complexity score to planning and budgeting in the German diagnosis-related groups system.

Authors:  Nicodème Sinzobahamvya; Joachim Photiadis; Thorsten Kopp; Claudia Arenz; Christoph Haun; Ehrenfried Schindler; Viktor Hraska; Boulos Asfour
Journal:  Pediatr Cardiol       Date:  2011-07-29       Impact factor: 1.655

2.  The impact of gestational age on resource utilization after open heart surgery for congenital cardiac disease from birth to 1 year of age.

Authors:  Naomi B Bishop; Theresa X Zhou; Jonathan M Chen; Mary J Ward; Sheila J Carroll
Journal:  Pediatr Cardiol       Date:  2012-10-21       Impact factor: 1.655

3.  The RACHS-1 risk category can be a predictor of perioperative recovery in Asian pediatric cardiac surgery patients.

Authors:  Yoshinobu Nakayama; Masayuki Shibasaki; Nobuaki Shime; Yasufumi Nakajima; Toshiki Mizobe; Teiji Sawa
Journal:  J Anesth       Date:  2013-06-06       Impact factor: 2.078

4.  Predicting the risk of infant mortality for newborns operated for congenital heart defects: A population-based cohort (EPICARD) study of two post-operative predictive scores.

Authors:  Nathalie Lelong; Karim Tararbit; Lise-Marie Le Page-Geniller; Jérémie Cohen; Souad Kout; Laurence Foix-L'Hélias; Pascal Boileau; Martin Chalumeau; François Goffinet; Babak Khoshnood
Journal:  Health Sci Rep       Date:  2021-05-19

5.  Weight-for-age standard score - distribution and effect on in-hospital mortality: A retrospective analysis in pediatric cardiac surgery.

Authors:  Antony George; Pushpa Jagannath; Shreedhar S Joshi; A M Jagadeesh
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

6.  Intravenous morphine versus intravenous paracetamol after cardiac surgery in neonates and infants: a study protocol for a randomized controlled trial.

Authors:  Gerdien A Zeilmaker-Roest; Joost van Rosmalen; Monique van Dijk; Erik Koomen; Nicolaas J G Jansen; Martin C J Kneyber; Sofie Maebe; Greet van den Berghe; Dirk Vlasselaers; Ad J J C Bogers; Dick Tibboel; Enno D Wildschut
Journal:  Trials       Date:  2018-06-13       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.